Japanese Mergers Provide Opening For Biotech Deals - Novartis Licensing Head
This article was originally published in PharmAsia News
Executive Summary
Recent mergers in the Japanese pharmaceutical market have provided U.S. and European biotechs enhanced opportunities to partner with Japanese pharmas looking to fill pipelines and compete globally, according to Novartis Global Head of Business Development and Licensing Anthony Rosenberg. However, Rosenberg cautioned that this same dynamic also could mean fewer opportunities for multinational pharmas to license compounds from their Japanese counterparts